The investigator-initiated clinical study (IIT clinical study) conducted in China of GPN02006, a global innovative radionuclide-drug conjugate (RDC) for diagnosis of hepatocellular carcinoma (HCC), has achieved a milestone breakthrough recently. The clinical results were published at the Chengdu 2025 Future XDC New Drug Conference.
Clinical study data show that GPN02006 exhibits excellent safety and imaging efficacy: all subjects did not report any drug related adverse reactions after administration, and the safety and tolerability were excellent; high quality imaging can be achieved 30 minutes after administration, fully meeting the clinical needs for rapid diagnosis of hepatocellular carcinoma.
The product has three significant advantages in imaging quality: extremely low background signal; high uptake specific to HCC lesions; and excellent diagnostic contrast. Based on its unique molecular targeting mechanism, the product can achieve: early and precise localization of HCC lesions; dynamic evaluation of treatment response; and early warning of recurrence and metastasis.
